In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...

Monoclonal antibodies (mAbs) are highly specific, laboratory-produced antibodies designed to target a single specific epitope or binding site on an antigen. Unlike polyclonal antibodies, which are a ...

The brain of a rat in which a fluorescent protein has been used to highlight transplanted human brain cells - Copyright Stanford University/AFP Sergiu PASCA The brain ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...

Monoclonal antibodies (mAbs) make up one of the most important classes of advanced biotherapies. To find out about the current challenges and advances in the production of mAbs, GEN talked with Lukas ...

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic(R) technology has been licensed by Ginkgo ...

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of blood cancer that that develops from B cell precursors. Healthy B cells produce a broad range of infection-fighting antibodies, making them ...

Monoclonal antibodies (mAbs) are manufactured proteins that behave similarly to antibodies found naturally in the body. Researchers initially developed them for treating certain cancers but have now ...